<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00930241</url>
  </required_header>
  <id_info>
    <org_study_id>5281M mono</org_study_id>
    <nct_id>NCT00930241</nct_id>
  </id_info>
  <brief_title>Twice Daily Versus Once Daily Administration of the Tacrolimus in Lung Transplantation</brief_title>
  <official_title>Prospective Randomized Trial to Compare a Twice Daily to a Once Daily Administration of the Tacrolimus in Lung Transplanted Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hannover Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective randomized trial to compare twice daily to once daily&#xD;
      administration of the basic immunosuppressive regimen in lung transplanted patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prevalence data of non-compliance in solid organ transplantations fluctuate is reported in up&#xD;
      to 39% of transplant recipients (z. B. for lung transplantations 13 - 22%; Kugler et al.).&#xD;
      Non-compliance with immunosuppressive therapy is associated with an increased risk of&#xD;
      late-acute rejections and the development of chronic transplant dysfunction. Chronic&#xD;
      transplant dysfunction (bronchiolitis obliterans- syndrome-BOS) is the second most causing&#xD;
      for organ failure after the first year following lung transplantation and often leads to&#xD;
      re-transplantation or death. Preventative procedures for improving the compliance are&#xD;
      simplification of the dose of the immunosuppressants (a once daily dose instead of a twice&#xD;
      daily dose), the prescription of an immunosuppressants with less side-effects and to raise&#xD;
      the patient´s awareness for having the greatest responsibility for the efficacy of his&#xD;
      therapy. Prospective studies and metaanalysis revealed that the probability for a good&#xD;
      compliance can be more than doubled at once daily administration in comparison to twice daily&#xD;
      and the best predictor for a good compliance is an easy therapy. For this reason we want to&#xD;
      investigate the extent of profit for our lung transplant patients receiving once daily basis&#xD;
      immunosuppression in comparison to those who receive twice daily dose.&#xD;
&#xD;
      Hypothesis: Patients of the once daily administration group of the immunosuppressive&#xD;
      medication will have a better compliance compared to the twice daily group (as measured by&#xD;
      the endpoints variability and medication abstraction from the electronic devices)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    logistic reasons (insufficient funding, technical problems with MEMS)&#xD;
  </why_stopped>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of adherence as measured by Tacrolimus trough level below the target level and dispensing of less than 50% of the prescribed doses in the last three days measured electronically before this subtherapeutic drug monitoring</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Deterioration of graft function (FEV1) before and at month 12 after conversion</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of drug holidays (intake of less than 50% of prescribed doses in 24 hours) measured electronically</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Lung Transplantation</condition>
  <arm_group>
    <arm_group_label>Advagraf</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Advagraf® (one daily dose of Tacrolimus)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prograf</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prograf® (two daily doses of Tacrolimus)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Advagraf®</intervention_name>
    <description>Advagraf® (one daily dose of Tacrolimus)</description>
    <arm_group_label>Advagraf</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prograf®</intervention_name>
    <description>Prograf® (two daily doses of Tacrolimus)</description>
    <arm_group_label>Prograf</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients (Pts) more than 1 year after single lung, double lung or heart/lung&#xD;
             transplantation&#xD;
&#xD;
          -  Pts treated with cyclosporin, steroids and MMF&#xD;
&#xD;
          -  Pts ≥ 18 and ≤ 70 years and&#xD;
&#xD;
          -  Pts with one of the following:&#xD;
&#xD;
               -  pts with recurrent acute rejections (RAR)&#xD;
&#xD;
               -  two or more acute rejections in 3 months (first 3 years post Tx, 6 months (&gt; 3&#xD;
                  years post Tx) defined by:&#xD;
&#xD;
                    -  transbronchial biopsy &gt; A1 (or A1 with clinical criteria below) nach ISHLT&#xD;
                       (B&gt;1R) or&#xD;
&#xD;
                    -  decline of FEV1 &gt; 10 % baseline after exclusion of infection, airway&#xD;
                       complication, effusion etc. and improvement to steroid-pulse therapy&#xD;
                       (methylprednisolone 15 mg/kg for three days) = FEV1 improvement &gt; 10%&#xD;
                       compared to the last measurement before AR treatment&#xD;
&#xD;
          -  Pts with steroid-resistant or ongoing acute rejections (OAR) defined by:&#xD;
&#xD;
               -  transbronchial biopsy &gt; A1 (or A1 with clinical criteria above) at least 4 weeks&#xD;
                  following steroid-pulse therapy (methylprednisolone 15 mg/kg for three days) or&#xD;
&#xD;
               -  no FEV1 improvement (&lt; 5% baseline) at least 14 days following ACR steroid-pulse&#xD;
                  therapy (methylprednisolone 15 mg/kg for three days) after exclusion of&#xD;
                  infection, airway complication, effusion etc. or&#xD;
&#xD;
          -  Pts with new onset of BOS (nBOS) Unexplained FEV1 &lt; 80% of baseline after exclusion of&#xD;
             Infection, airway complication, effusion etc&#xD;
&#xD;
          -  Pts with CyA associated side effects (e.g., hyperlipidaemia, hypertriglyceridemia,&#xD;
             hypertension, hirsutism, gingival hyperplasia)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breast feeding women&#xD;
&#xD;
          -  Pts who are not using a double-barrier method of birth control&#xD;
&#xD;
          -  Pts with systemic infections&#xD;
&#xD;
          -  Pts with severe diarrhea, vomiting, active ulcer&#xD;
&#xD;
          -  Pts with severe liver disease or liver cirrhosis&#xD;
&#xD;
          -  Pts with m-Tor inhibitors&#xD;
&#xD;
          -  Pts with hypersensitivity to Tacrolimus, other macrolides or other tablet ingredients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens T Gottlieb, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Respiratory Medicine, Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hannover Medical School, Dept. of Respiratory Medicine</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>June 29, 2009</study_first_submitted>
  <study_first_submitted_qc>June 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2009</study_first_posted>
  <last_update_submitted>August 21, 2018</last_update_submitted>
  <last_update_submitted_qc>August 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lung Transplantation</keyword>
  <keyword>Tacrolimus</keyword>
  <keyword>Deterioration of graft function</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

